Drug Products Labeled as Homeopathic Guidance for FDA Staff and Industry

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within ___ days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to https://www.regulations.gov. Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.

For questions regarding this draft document contact the Center for Drug Evaluation and Research (CDER) at 301-796-2089 or the Office of Communication, Outreach and Development (CBER), 800-835-4709 or 240-402-8010.

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)

December 2017
Compliance
Drug Products Labeled as Homeopathic
Guidance for FDA Staff and Industry

Additional copies are available from:
Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10001 New Hampshire Ave., Hillandale Bldg., 4th Floor
Silver Spring, MD 20993-0002
Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353
Email: druginfo@fda.hhs.gov
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm

and/or
Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 71, Room 3128
Silver Spring, MD 20993-0002
Phone: 800-835-4709 or 240-402-8010
Email: ocod@fda.hhs.gov

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)

December 2017
Compliance
TABLE OF CONTENTS

I. INTRODUCTION.......................................................................................................................... 1

II. BACKGROUND ............................................................................................................................ 1
   A. Compliance Policy Guide 400.400 ................................................................................... 3
   B. FDA’s Reexamination of its Enforcement Policies ........................................................ 3
   C. FDA’s Risk-based Approach ........................................................................................... 3

III. FDA’s ENFORCEMENT POLICY ............................................................................................. 4
I. INTRODUCTION

This draft guidance describes how we intend to prioritize enforcement and regulatory actions for human drug products labeled as homeopathic and marketed in the United States without the required FDA approval. As discussed below, FDA has developed a risk-based approach under which the Agency intends to prioritize enforcement and regulatory actions involving certain categories of such products that potentially pose a higher risk to public health. However, the Agency also recognizes that many products labeled as homeopathic will fall outside the risk-based categories described below.

Simultaneous with the issuance of the final guidance, we will withdraw Compliance Policy Guide (CPG) 400.400, Conditions Under Which Homeopathic Drugs May be Marketed issued on May 31, 1988.

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

II. BACKGROUND

Homeopathy is an alternative medical practice that has a historical basis in theory and practice first systematized in the late 1700s. Homeopathy is generally based on two main principles: (1) that a substance that causes symptoms in a healthy person can be used in diluted form to treat
symptoms and illnesses (known as “like-cures-like”); and (2) the more diluted the substance, the
more potent it is (known as the “law of infinitesimals”). Proponents claim that a significantly
diluted aqueous solution, consisting mainly of water molecules, retains therapeutic properties
due to a “memory” of the substance diluted in it. Historically, homeopathic drugs have been
identified through “provings,” in which substances are administered to healthy volunteers in
concentrations that provoke overt symptoms. Symptoms experienced by volunteers are recorded
to indicate possible therapeutic uses for the substances. In other words, if a substance elicits a
particular symptom, individuals experiencing that symptom would be treated with a diluted
solution made from that substance.

In 1938, when the Federal Food, Drug, and Cosmetic Act (FD&C Act) was enacted, the bill’s
senatorial sponsor, Dr. Royal Copeland, himself a homeopathic practitioner, added a provision to
the law recognizing the Homeopathic Pharmacopoeia of the United States (HPUS) alongside its
counterparts, the U.S. Pharmacopeia and the National Formulary.3 Recent years have seen an
increase in the sale of products labeled as homeopathic. In the past, these products were mostly
prepared by homeopathic physicians for individual patients. Today they are frequently mass
manufactured and widely marketed as over-the-counter (OTC) products.

The definition of “drug” in section 201(g)(1) of the FD&C Act (21 U.S.C. 321(g)) includes
articles recognized in the HPUS or any of its supplements. As such, homeopathic drugs are
subject to the same regulatory requirements as other drugs. Generally, a drug, including a
homeopathic drug, is considered a “new drug” if it is not generally recognized as safe and
effective (GRAS/E) by qualified experts for use under the conditions prescribed, recommended,
or suggested in the labeling (section 201(p) of the FD&C Act) (21 U.S.C. 321(p)). FDA makes
GRAS/E determinations for OTC drugs marketed under the OTC Drug Review.4 The FDA has
not reviewed any drug products labeled as homeopathic under the OTC Drug Review, because
the Agency categorized these products as a separate category and deferred consideration of them.
(37 FR 9464, 9466 (May 11, 1972)). Under section 505(a) of the FD&C Act (21 U.S.C. 355(a)),
before any “new drug” is marketed, it must be the subject of an approved application filed
pursuant to section 505(b) or section 505(j) of the FD&C Act; however, a biological product
with an approved license under section 351(a) of the Public Health Service Act (PHS Act) (42
U.S.C. 262(a)) is not required to have an approved application under section 505 of the FD&C
Act. Accordingly, absent a determination that a drug product labeled as homeopathic is not a
“new drug” under section 201(p), all drug products labeled as homeopathic are subject to the
premarket approval requirements in section 505 of the FD&C Act or section 351 of the PHS Act.
There are no drug products labeled as homeopathic that are approved by FDA.

The FDA’s evidence-based systems for the review of drugs under new drug applications
(NDAs), biologics license applications (BLAs), and the OTC Drug Review play an essential role
in ensuring that drugs are both safe and effective.5 Drugs marketed without required FDA
approval may not meet modern standards for safety, effectiveness, quality, and labeling. The

---

3 Section 201(g)(1) of the FD&C Act.
4 See 21 CFR part 330.
5 For instance, during the new drug application approval process the applicant must demonstrate that its
manufacturing processes can reliably produce drug products of expected identity, strength, quality, and purity. 21
CFR 314.50(d)(1)(ii)(a).
continued marketing of products that have neither been approved by FDA nor found to be
GRAS/E is a public health concern.

A. Compliance Policy Guide 400.400

In May 1988, the Center for Drug Evaluation and Research issued Compliance Policy Guide
400.400 entitled “Conditions Under Which Homeopathic Drugs May be Marketed.” As stated in
the 1988 CPG, it delineates the conditions, including ones regarding ingredients, labeling,
prescription status, and current good manufacturing practice, under which homeopathic drug
products may ordinarily be marketed.

B. FDA’s Reexamination of its Enforcement Policies

In light of the growth of the industry and passage of more than 2 decades since the issuance of
the 1988 CPG, FDA announced on March 27, 2015, that it was evaluating its regulatory
framework for these products.6 In April 2015, FDA held a public hearing to obtain information
and comments from stakeholders about the current use of drug products labeled as homeopathic,
as well as the Agency’s regulatory framework for such products.7 FDA sought broad public
input on its enforcement policies related to drug products labeled as homeopathic in an effort to
better promote and protect the public health. As a result of the Agency’s evaluation, including
consideration of the information obtained as a result of the public hearing, FDA has determined
that it is in the best interest of public health to issue a new guidance that applies a risk-based
enforcement approach to drug products labeled as homeopathic and marketed without the
required FDA approval, consistent with FDA’s risk-based regulatory approaches generally.

C. FDA’s Risk-based Approach

In many instances, FDA uses a risk-based approach to carry out its mandates. For
example, FDA has generally employed a risk-based enforcement approach with respect to
marketed unapproved new drugs.8 The Agency historically has prioritized compliance
actions involving unapproved new drug products that have potential safety risks, lack
evidence of effectiveness, are health fraud products, present challenges to the new drug
approval or OTC drug monograph systems under the OTC Drug Review, are violative of
the FD&C Act in other ways, or that are reformulated to evade an FDA enforcement
action.

The Agency generally intends to apply a risk-based enforcement approach to the manufacturing,
distribution, and marketing of drug products labeled as homeopathic, as described below.

---

6 80 FR 16327, Homeopathic Product Regulation: Evaluating the Food and Drug Administration’s Regulatory
Framework After a Quarter-Century.
8 See Marketed Unapproved Drugs - Compliance Policy Guide, Section 440.100, September 19, 2011. We update
guidances periodically. To make sure you have the most recent version of a guidance, check the FDA Drugs
III. FDA’s ENFORCEMENT POLICY

The issuance of this guidance, when finalized, is intended to provide notice that any product labeled as homeopathic that is being marketed illegally is subject to FDA enforcement action at any time. FDA is not required, and generally does not expect, to give special notice that a drug product may be subject to enforcement action. However, in the listing that follows, we clarify our approach to prioritizing our enforcement actions with regard to drug products labeled as homeopathic and marketed in the United States without the required FDA approval.

Enforcement and Regulatory Priorities

In developing a risk-based approach, FDA has identified certain categories of drug products labeled as homeopathic and marketed without the required FDA approval as potentially posing higher risks to public health. FDA intends to prioritize enforcement and regulatory actions involving drug products labeled as homeopathic and marketed without the required FDA approval in the following categories:

- **Products with reported safety concerns.** For example, MedWatch reports or other information submitted to the Agency can indicate or signal a potential association between the product and an adverse event, medication errors, or other safety issues.

- **Products that contain or purport to contain ingredients associated with potentially significant safety concerns.** For example, potentially significant safety concerns are raised by products that contain or purport to contain:
  - An infectious agent with the potential to be pathogenic;
  - A controlled substance, as defined in the Controlled Substances Act, 21 U.S.C. 812;
  - Multiple ingredients that, when used in combination, raise safety concerns due to possible interactions, synergistic effects, or additive effects of the various ingredients; and,
  - Ingredients that pose potential toxic effects, particularly when those ingredients are concentrated or in low dilution presentations (e.g., 1X, 2X, or 1C), or are not adequately controlled in the manufacturing process.

- **Products for routes of administration other than oral and topical.** For example, unapproved injectable drug products and unapproved ophthalmic drug products pose a greater risk of harm to users due to their routes of administration (e.g., bypassing some of the body’s natural defenses, differences in absorption) and the potential risk of harm from contamination.

- **Products intended to be used for the prevention or treatment of serious and/or life-threatening diseases and conditions.** Unapproved products for serious and/or life-threatening diseases and conditions raise public health concerns, in part, because they may cause users to delay or discontinue medical treatments that have been found safe and
effective through the NDA or BLA approval processes.

• **Products for vulnerable populations.** For example, patient populations such as immunocompromised individuals, infants and children, the elderly, and pregnant women may be at greater risk for adverse reactions associated with a drug product, even if it contains only small amounts of an ingredient, due to their varying ability to absorb, metabolize, distribute, or excrete the product or its metabolites. These populations may also be at greater risk of harm as a result of foregoing the use of medical treatments that have been found safe and effective through the NDA or BLA approval processes or under the OTC Drug Review.

• **Products deemed adulterated under section 501 of the FD&C Act.** For example, if a product purports to be or is represented as a product recognized in an official compendium but its strength, quality, or purity differs from the standards set forth in that official compendium (defined by 21 U.S.C. 321 as the official United States Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, official National Formulary, or any supplement to any of them), or if there are significant violations of current good manufacturing practice requirements.